Please select the option that best describes you:
What is your approach to the use of denosumab in patients with metastatic breast cancer with bony involvement?
Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to every 3 weeks? If so, do you start this schedule with the first dose or after a "lead in" period?
Answer from: Medical Oncologist at Academic Institution
I do not extrapolate the results of OPTIMIZE-2 and CALGB 70604 to denosumab. It is a different drug and until appropriate studies are performed, there is no reason to change its dose or schedule.
Sign in or Register to read more